KR20190073967A - Composition for Improving Exercise Performance comprising Soy Protein Isolates and Curcumin - Google Patents

Abstract

The present invention provides a functional health food for improving exercise performance, a pharmaceutical composition for preventing or treating muscle diseases, a pharmaceutical composition for preventing or treating dyslipidemia, and a functional health food for lowering blood triglycerides. The present invention provides an effect of improving muscular strength and endurance. When the functional health food of the present invention is used, it is possible to simultaneously obtain the effect of improving exercise performance and blood lipid profile.

Description

TECHNICAL FIELD The present invention relates to a composition for improving exercise performance, which comprises soy protein isolate and curcumin.

The present invention relates to a composition for improving exercise performance, which comprises isolated soybean protein and curcumin.

Muscle strength means the greatest power that muscles and muscle tissues can exert, and exercise performance refers to the ability to use these strengths to quickly, strongly, professionally perform body movements performed in daily life or in sports. When muscles are lost due to inherited causes such as disability of the body or laying in the hospital for a long period of time, muscular strength is decreased and exercise performance is decreased. Therefore, it is required to enhance exercise performance. It is required to enhance the exercise performance.

As a method for enhancing exercise performance, scientific training, dietary therapy, improvement of technical equipment and ergogenic aids are being used according to sports events. Of the above methods, studies related to functional adjuvants for improving exercise performance have been actively carried out, both east and west. However, the athletic performance supplements used in the West are mostly caffeine, anabolic steroids, etc., and there is a risk of doping. Recently, studies for developing a functional adjuvant using safety-guaranteed natural materials have been actively carried out. However, studies on adjuvant without a side effect are desired while effectively enhancing exercise performance and being ineffective.

On the other hand, as a prior art related to the enhancement of exercise performance, Patent No. 10-1191081 discloses a mistletoe extract having an effect of enhancing exercise performance and suppressing fatigue, and Japanese Patent No. 10-1675064 discloses an exercise A composition for enhancing performance and improving physical fitness has been disclosed, and a composition for promoting athletic performance and fatigue recovery has been disclosed in Japanese Patent No. 10-1120996 including ginsenosides Rg3 and Rg2.

Patent No. 10-1191081 Patent No. 10-1675064 Registration No. 10-1120996

The present inventors have tried to develop a composition capable of improving exercise performance. As a result, the present invention has been completed by confirming the effect of improving the exercise performance of the isolated soybean protein and curcumin mixture.

Accordingly, an object of the present invention is to provide a health functional food for improving exercise performance.

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating muscle diseases.

It is another object of the present invention to provide a pharmaceutical composition for the prevention or treatment of dyslipidemia.

Another object of the present invention is to provide a health functional food for improving serum triglyceride.

According to one aspect of the present invention, there is provided a health functional food for improving exercise performance comprising an isolated soybean protein and curcumin as an active ingredient.

The present inventors have tried to develop a composition capable of improving exercise performance. As a result, the effect of improving the exercise performance of isolated soy protein and curcumin mixture was confirmed.

As used herein, the term "isolated soy protein" or "soy protein isolate " (SPI) refers to a protein derived from soybean ( Glycine max ). The isolated soybean protein is a protein separated from soybean, and the protein content may be 70%, 80% or 90% or more. The isolated soybean protein can be obtained by extracting defatted soybean meal with oil or salt.

As used herein, the term "curcumin" is a type of alkaloid that is predominantly contained in Curcuma longa and refers to a compound having the structure of the following formula:

[Chemical Formula]

As used herein, the term "athletic performance ability" means an ability to rapidly, strongly, long, and skillful body movements performed in daily life or sports. The exercise performance is largely divided into 1) restoration of muscular dystrophy, 2) endurance, 3) activation of muscular nervous system, and the health functional food for improving exercise performance of the present invention has an endurance improving effect.

The endurance is defined as the 'resistance to fatigue'. This means resistance to fatigue that occurs during motion that lasts maximum (before maximum force) or during intense motion.

The health functional food for improving exercise performance of the present invention contains isolated soybean protein and curcumin as active ingredients. The curcumin is insoluble in water, and the health functional food for improving exercise performance of the present invention may further include an emulsifier to mix the curcumin and the isolated soy protein.

According to an embodiment of the present invention, the emulsifier may be selected from the group consisting of polyglycerol polyricinoleate (MGP), acetylated monoglycerides (AMG), lactated monoglycerides (LMG), citric acid esters of monoglycerides (CMG), succinic acid esters of monoglycerides ), DATEM (diacetyl tartaric acid esters of monoglycerides), PGE (polyglycerol ester of fatty acids), SOE (sorbitan ester of fatty acids), PGME (propylene glycol ester of fatty acids), SE at least one emulsifier selected from the group consisting of calcium stearoyl diacetate, LC (lecithin) and enzyme-treated LC.

According to another embodiment of the present invention, the emulsifier is PGPR.

PGPR is an emulsifier isolated from castor bean oil and plays a role in reducing interfacial tension in the multiphase system through its amphipathic nature. In particular, it has the ability to stabilize water-in oil emulsions with powerful oil-soluble surfactants.

When the composition of the present invention is manufactured from a health functional food composition, it includes components that are conventionally added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, in the case of a drink preparation, a flavoring agent or a natural carbohydrate may be added as an additional ingredient in addition to the compound of the formula (1) as an active ingredient. For example, natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.); Disaccharides (e.g., maltose, sucrose, etc.); oligosaccharide; Polysaccharides (e.g., dextrin, cyclodextrin and the like); And sugar alcohols (e.g., xylitol, sorbitol, erythritol, etc.). Natural flavoring agents (e.g., tau marin, stevia extract, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) may be used as flavorings.

According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating a muscle disorder comprising an isolated soybean protein and curcumin as an active ingredient.

As used herein, the term "muscle disorder" refers to an external factor such as contusion, laceration, crush, internal factors such as sudden or severe falls or muscle strain during sports activities, Is meant to include muscle damage, muscle wasting, and / or loss of muscle function resulting from the interruption of possible blood supply, which may be due to genetic and / or environmental factors .

According to one embodiment of the present invention, the muscle disease is selected from the group consisting of muscular atrophy, sacopenia, muscular dystrophy, ataxia, atony, muscular dystrophy, ≪ / RTI > or more. Specifically, the muscle disease is at least one selected from the group consisting of muscular dystrophy, muscular dystrophy, muscular dystrophy, ataxia, or tense depression.

The muscular atrophy of the limbs causes progressive denaturation of the motor nerve fibers and cells in the spinal cord and causes amyotrophic lateral sclerosis (ALS) and spinal progressive muscular atrophy (SPMA) ). ≪ / RTI >

The term "myopenia" means a gradual decrease in skeletal muscle mass due to aging, which directly leads to a decrease in muscle strength, resulting in a decrease in various body functions and a disorder.

The above-mentioned 'muscle degeneration atrophy' is a disease in which gradual muscular atrophy and muscle weakness appear, which means degenerative myopathy characterized by necrosis of muscle fibers pathologically.

The 'heart atrophy' is a condition in which the heart is contracted by an external or internal factor, such as starvation, consuming disease, and aging, which causes the myocardial fiber to become thinner and thinner, leading to a decrease in adipose tissue.

As used herein, the term "prophylactic " means any action that inhibits or slows down the progression of a muscle disease by administration of the composition of the present invention.

As used herein, the term "treatment" refers to inhibition of the development of muscle disorders; Relief of muscle disorders; And removal of muscle diseases.

The pharmaceutical composition of the present invention can be used as a pharmaceutical composition comprising a pharmaceutically effective amount of isolated soybean protein and curcumin and / or a pharmaceutically acceptable carrier.

As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient to achieve efficacy or activity of isolated soy protein and curcumin.

The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components.

The pharmaceutical compositions according to the present invention can be administered to mammals, including humans, in a variety of routes. The mode of administration may be any conventional manner and may be administered, for example, by oral, skin, intravenous, intramuscular, subcutaneous, and the like routes, preferably orally.

The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-1000 mg / kg.

The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets, capsules or gels (e.g., hydrogels), and may additionally contain dispersing or stabilizing agents .

According to still another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating dyslipidemia comprising an isolated soybean protein and curcumin as an active ingredient.

As used herein, the term "dyslipidemia" refers to a condition caused by metabolic abnormalities of lipoprotein, which means that the blood contains excess lipid or fat component. The above-mentioned dyslipidemia is manifested in the form of high LDL-cholesterol level, high total cholesterol level, hypertriglyceridemia and low HDL-cholesterol level by increasing the biosynthesis of lipoproteins that transport cholesterol and triglyceride or decreasing degradation.

According to one embodiment of the present invention, the composition has the effect of reducing at least one lipid selected from the group consisting of blood triglyceride, total cholesterol, LDL-cholesterol and free fatty acid.

According to another aspect of the present invention, there is provided a health functional food for improving serum triglycerides comprising an isolated soy protein and curcumin as an active ingredient.

The pharmaceutical composition for the prevention or treatment of muscle disorders of the present invention, the pharmaceutical composition for the prevention or treatment of dyslipidemia, and the health functional food for the improvement of blood triglyceride containing the isolated soybean protein and curcumin as an active ingredient, The same functional ingredient as the health functional food for ability enhancement, so that the description common to them is omitted in order to avoid the excessive complexity of the present specification.

The features and advantages of the present invention are summarized as follows:

(a) The present invention provides a health functional food for improving exercise performance, a pharmaceutical composition for preventing or treating muscle diseases, a pharmaceutical composition for preventing or treating dyslipidemia, and a health functional food for improving blood triglyceride.

(b) The present invention provides an effect of improving strength and endurance.

(c) When a health functional food containing the isolated soybean protein and curcumin of the present invention is used, it is possible to simultaneously obtain an effect of improving exercise performance and improving blood lipid.

Figure 1 shows the effect of diets on SPI, CCM and SPI + CCM complexes on glucose in obese animal models.
Figure 2 shows the effect of diet on SPI, CCM and SPI + CCM complex on blood triglyceride in obese animal models.
Figure 3 shows the effect of dietary SPI, CCM and SPI + CCM complex on total cholesterol in the obese animal model.
Figure 4 shows the effect of diets on SPI, CCM and SPI + CCM complex on low density lipoprotein cholesterol (LDL-cholesterol) in obese animal models.
Figure 5 shows the effect of diet of SPI, CCM and SPI + CCM complex on non-esterified fatty acids in obese animal models.
Figure 6 shows the effect of diet on SPI, CCM and SPI + CCM complexes on grip strength of obese animal models.
Figure 7 shows the effect of diet on SPI, CCM and SPI + CCM complexes for distance to exhaustion of obese animal models.
Figure 8 shows the effect of diet of SPI, CCM and SPI + CCM complex on time to exhaustion of obese animal models.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Throughout this specification, "%" used to denote the concentration of a particular substance is intended to include solids / solids (wt / wt), solid / liquid (wt / The liquid / liquid is (vol / vol)%.

Example 1: Preparation of isolated soy protein-curcumin complex

The O / W emulsion method was used to prepare curcumin (Sigma Aldrich, C1386) complexes (Soy Protein, Separated Soy Protein, Batch No. J98) (Volume) = 1: 3).

First, 100 mg of cholecalciferol (Sigma Aldrich, C9756), 10 g of PGPR (polyglycerol polyricinoleate, Palsgaard, Denmark) and curcumin (100 mg) were dissolved in 100 g of soybean oil Respectively. Next, an aqueous phase was prepared from distilled water containing 0.1% isolated soybean protein, and the aqueous phase was mixed with the oil phase prepared in the above step 1: 3 (oil phase: water phase) to prepare an O / W emulsion. Homogenization was performed at 6000 bar.

According to the above method, SPI, or three samples of CCM and SPI + CCM composite were prepared. The SPI was prepared by mixing an oil phase containing no curcumin and an aqueous phase containing separated soybean protein. The CCM was prepared by mixing an oil phase containing curcumin and an SPI-free aqueous phase.

The residual curcumin was removed from the prepared CCM and SPI + CCM complexes and analyzed by HPLC. The curcumin content was 151.11 ± 4.93 ug / mL. The content of SPI in the SPI and SPI + CCM complexes is about 750 ug / ml (0.075%).

Example 2: Animal breeding

To measure the tongue and endurance potency of the SPI + CCM complex, C37BL / 6N 5 week old male mice weighing 17-20 g were purchased from Orient Bio.

During the experimental period, the temperature of the breeding room was maintained at 22 ± 10 ℃ and the humidity was maintained at 50 ± 10%. The day and night cycle was automatically adjusted to 12 hours.

All the experimental groups were divided into 5 groups. (HFD AIN-93 diet, 60% fat, Harlan laboratories Inc.) were fed a normal diet (chow, Harlan Laboratories Inc.) in the NOR group and CON, SPI, CCM and SPI + I was paid.

In order to investigate the effect of SPI + CCM complex, SPI, CCM and SPI + CCM complex were orally administered to SPI group, CCM group and SPI + CCM group, respectively.

The oral dose of CCM and SPI + CCM complexes maintained a curcumin content of about 30 ug.

Example 3: Blood analysis

Blood glucose was measured in Accu-Check Active (Roche) after collecting blood from the tail vein of the mouse. All mice were weighed every week and blood glucose was measured every two weeks to confirm the effect of the SPI-CCM complex on weekly changes.

During the experimental period, the CCM group and the SPI + CCM group showed statistically significant decrease compared to the CON group and the SPI group at the 6th week of the experiment. In the 8th week of the experiment, however, statistical significance (Fig. 1).

The serum cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and nonesterified fatty acid (NEFA) MMBI Co., Ltd.).

TG is the accumulation of surplus energy in the body in the form of triglycerides, which together with cholesterol cause coronary artery disease. Compared with the CON group, the CCM group decreased by 24.68% and the SPI + CCM group decreased by 37.31%.

In order to investigate the effect of SPI + CCM complex on TG reduction, SPI + CCM group showed a statistical difference by 12.64% more than CCM group (Fig. 2).

TC was decreased by 17.14% in SPI + CCM group compared to CON group, and showed a statistically significant difference compared with SPI group and CCM group (Fig. 3).

LDL-C deposits on the blood vessel wall, which makes the blood vessels hard and causes arteriosclerosis. The SPI + CCM group showed a statistically significant difference in the SPI + CCM group by 45.7% compared to the CON group. The SPI + CCM complex was compared with the SPI + CCM group (35.48%) compared to the CCM group (Fig. 4).

NEFA is measured to evaluate serum free fatty acids. Compared with the CON group, the SPI + CCM group showed a 35.09% decrease, showing a statistically significant difference, compared to the CCM group (FIG. 5).

Example 4: Athletic performance analysis

For SPI-CCM composite exercise test. Grip strength test and treadmill test were conducted at the end of the experiment.

Grip test

For the grip strength test, the grip strength was measured using a force measuring device for the mouse of BIOSEB. The power of the mouse was measured by pulling down the tail of the mouse on the wire mesh attached to the instrument panel to monitor the strength of the force and pulling it downward. The test was repeated 5 times in succession.

As a result of grip strength test, there was no statistically significant difference between CON and SPI groups in the CON group (69.31 ± 5.59 g) compared with the NOR group (87.88 ± 6.90 g). The SPI + CCM group (90.14 ± 2.59 g) showed increased grip compared with the SPI group (66.51 ± 6.23 g) and the CCM group (81.73 ± 1.49 g), which was higher than the NOR group (Figure 6).

In order to clarify the effect of SPI + CCM complex, the SPI + CCM group showed statistically significant higher grip strength than the CCM group. As a result, SPI + CCM complex (Fig. 6).

Treadmill Test

For the treadmill test, a treadmill (Dual treadmill, Daejong Intrument) was used for the mouse, and an electric stimulus was made to flow at the starting point. The treadmill test was carried out by warming up the angle by 5 ° for 5 minutes at 5 m / min and 10 min at 10 m / min. On the day of measurement, the mice were run for 20 minutes at a speed of 10 m / min, and then the mice were measured for two minutes at 2 m / min until they were exhausted.

In the treadmill test, the CON group showed decreased exercise distance and time compared to the NOR group, and the SPI + CCM group showed significantly improved exercise performance. The SPI group was slightly lower than the CON group, confirming that there was no improvement in exercise performance as well as muscle strength. CCM group and SPI + CCM group showed statistically significant increase compared to CON group. Especially SPI + CCM group showed improved exercise distance and time to the level of NOR group (FIGS. 7 and 8).

Compared with the CCM group, the SPI + CCM group showed significantly higher treadmill test distance (Fig. 7) and time (Fig. 8) than the CCM group The results showed that SPI-CCM complex improves muscle strength and motor performance.

Claims (7)

A health functional food for improving exercise performance comprising an isolated soybean protein and curcumin as active ingredients.
The health functional food according to claim 1, wherein the composition improves muscle strength or endurance.
A pharmaceutical composition for preventing or treating a muscle disorder, which comprises isolated soybean protein and curcumin as an active ingredient.
4. The method of claim 3, wherein the muscle disorder is at least one selected from the group consisting of muscular atrophy, sacopenia, atony, muscular dystrophy, muscle degeneration, Wherein the composition is a muscle disease.
A pharmaceutical composition for preventing or treating dyslipidemia comprising an isolated soybean protein and curcumin as an active ingredient.
6. The composition of claim 5, wherein the composition reduces at least one lipid selected from the group consisting of blood triglyceride, total cholesterol, low density lipoprotein cholesterol, and free fatty acids.
Separated Soy Protein and Curcumin as Active Ingredients.

Images